4.5 Review

Frontiers of Antifibrotic Therapy in Systemic Sclerosis

Journal

ARTHRITIS & RHEUMATOLOGY
Volume 69, Issue 2, Pages 257-267

Publisher

WILEY
DOI: 10.1002/art.39865

Keywords

-

Categories

Funding

  1. Deutsche Forschungsgemeinschaft [DI 1537/5-1, DI 1537/7-1, DI 1537/8-1, DI 1537/9-1]
  2. Interdisciplinary Center for Clinical Research [A57, A62, J29]
  3. Else-Kroner-Fresenius Stiftung [2014_A248]
  4. Ernst Jung Foundation (Career Advancement Award for Medical Research)
  5. Actelion
  6. BMS
  7. Celgene
  8. Bayer Pharma
  9. Boehringer Ingelheim
  10. JB Therapeutics
  11. Sanofi-Aventis
  12. Novartis
  13. UCB
  14. GSK
  15. Array Biopharma
  16. Active Biotech
  17. 4D Science
  18. Bayer-Schering
  19. Biogen
  20. Biovitrum
  21. Boehringer
  22. EpiPharm
  23. ErgoNex
  24. Inventiva
  25. Medac
  26. Pfizer
  27. Roche/Genentech
  28. Sanofi/Genzyme
  29. Serodapharm
  30. Sinoxa
  31. United BioSource Corporation
  32. Versus Arthritis [19427, 18420] Funding Source: researchfish

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available